Clear Street Reiterates Buy Rating on Regenxbio Inc. (RGNX): "market is overly discounting the strength of early ‘202 data"
Tweet Send to a Friend
Clear Street analyst Bill Maughan reiterated a Buy rating and $45.00 price target on Regenxbio Inc. (NASDAQ: RGNX)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
